Clinical Trials on Influenza, Human in Russian Federation

Total 199 results

St. Petersburg Research Institute of Vaccines and...

Completed

Safety and Reactogenicity Trial of Vaccine for the Prevention of Infections Caused by Haemophilus Influenzae Type b

Vaccines | Haemophilus Influenzae Infection

Russian Federation
Gamaleya Research Institute of Epidemiology and...

Completed

The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac

Influenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1

Russian Federation
PATH
Institute of Experimental Medicine, Russia; Research Institute of Influenza... and other collaborators

Completed

Safety Trial of Live Attenuated Influenza (H7N3) Vaccine

Influenza | Avian Influenza

Russian Federation
AVIR Green Hills Biotechnology AG

Completed

Two Doses of GHB04L1 for Pandemic Influenza Prophylaxis in Healthy Adults

Influenza, Avian

Russian Federation
Pharmenterprises Biotech LLC

Completed

Study to Assess Safety, Tolerability and Reactogenicity of Vaccine "UniFluVec" After Two Intranasal Administrations in Healthy Volunteers

Influenza A

Russian Federation
PATH
Institute of Experimental Medicine, Russia; Research Institute of Influenza...

Completed

Immunogenicity of H5N1 Vaccine Following H5N2

Influenza Vaccine

Russian Federation
St. Petersburg Research Institute of Vaccines and...

Completed

The Objectives of This Study Are Study of the Reactogenicity, Safety and Immunogenicity of Flu-M Inactivated Split Influenza Vaccine in Volunteers Aged 18-60 Years

Influenza

Russian Federation
St. Petersburg Research Institute of Vaccines and...

Completed

The Objectives of This Study Are Study the Safety, Reactogenicity and Obtain Preliminary Data on the Immunogenicity of Flu-M Quadro, 4-valent Inactivated Split Influenza Vaccine, in Healthy Volunteers

Influenza

Russian Federation
St. Petersburg Research Institute of Vaccines and...

Completed

Tolerability, Safety and Immunogenicity Trial of the Flu-M® Inactivated Vaccine in Volunteers Aged 18 to 60 Years

Influenza | Flu, Human

Russian Federation
PATH
Institute of Experimental Medicine, Russia; Microgen

Completed

Reactogenicity, Safety, and Immunogenicity of a Live Monovalent H5N2 Influenza Vaccine

Influenza

Russian Federation
St. Petersburg Research Institute of Vaccines and...

Completed

The Objectives of This Study Are Study the Immunogenicity and Safety of the Flu-M [Inactivated Split Influenza Vaccine], vs. the Ultrix® Inactivated Split Influenza Vaccine, in Volunteers Who Are Over 60 Years Old

Influenza

Russian Federation
PATH
Institute of Experimental Medicine, Russia; Ministry of Health, Russian Federation

Completed

Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/CALIFORNIA/66/395 (H2N2) Influenza Vaccine

Influenza

Russian Federation
NPO Petrovax

Completed

A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus

Vaccine Reaction | Influenza | Influenza, Human | Influenza A | Acute Respiratory Infection | Influenza Type B | Flu | Influenza A H3N2 | Influenza A H1N1 | Flu, Human | Influenza Epidemic

Russian Federation
GlaxoSmithKline

Completed

A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia

Hepatitis B | Pertussis | Tetanus | Diphtheria | Haemophilus Influenzae Type b

Russian Federation
St. Petersburg Research Institute of Vaccines and...

Completed

The Objectives of This Study Are Comparative Assessment of the Tolerability, Safety and Immunogenicity of the Flu-M Vaccine vs. the Ultrix® Vaccine by Single Vaccination of Children Aged 6 to 17 Years.

Influenza

Russian Federation
St. Petersburg Research Institute of Vaccines and...

Completed

Trial of the Reactogenicity, Safety and Immunogenicity of the Flu-M Vaccine Manufactured by FSUE SPbSRIVS FMBA

Influenza

Russian Federation
NPO Petrovax

Completed

Safety, Reactogenicity, Immunogenicity, and Efficacy of Quadrivalent Inactivated Subunit Influenza Vaccine Grippol® Quadri and Trivalent Inactivated Polymer-Subunit Vaccine Grippol® Plus in Volunteers

Influenza

Russian Federation
Pharmstandard

Unknown

A Study of Arbidol (Umifenovir) for Treatment and Prophylaxis of Influenza and Common Cold (ARBITR)

Influenza

Russian Federation
Nearmedic Plus LLC

Completed

Treatment of Influenza and ARVI in Children by Kagocel ®

Influenza | Acute Upper Respiratory Infection

Russian Federation
Viriom

Not yet recruiting

Study Evaluating the Efficacy and Safety of AV5080 in Patients With Uncomplicated Influenza

Influenza

Russian Federation
VA Pharma Limited Liability Company

Unknown

Reactogenicity, Safety and Immunogenicity of an Universal Influenza Vaccine Uniflu

Safety Issues

Russian Federation
St. Petersburg Research Institute of Vaccines and...

Completed

Tolerability, Safety and Immunogenicity Trial of the FLU-M® Tetra

Influenza

Russian Federation
Materia Medica Holding

Completed

Clinical Trial of Clinical Efficiency and Safety of Ergoferon in Treatment of Influenza

Influenza

Russian Federation
St. Petersburg Research Institute of Vaccines and...

Recruiting

Tolerability, Safety and Immunogenicity Trial of the Flu-M Tetra Vaccine in Children

Vaccine Reaction | Influenza | Influenza, Human | Influenza Viral Infections

Russian Federation
Samara Regional Cardiology Dispensary

Recruiting

Influenza Vaccination During Coronavirus Disease 2019 Outbreak After Acute Coronary Syndrome and Chronic Heart Failure (IV-ACS&CHF)

Acute Coronary Syndrome | Chronic Heart Failure

Russian Federation
Materia Medica Holding

Completed

Comparative Clinical Trial of Efficacy and Safety of Ergoferon Versus Oseltamivir in Treatment of Influenza

Influenza

Russian Federation
Nearmedic Plus LLC

Completed

Kagocel® for the Prevention of ARVI and Influenza in Young People

Influenza | Respiratory Viral Infection | Acute Upper Respiratory Tract Infection

Russian Federation
St. Petersburg Research Institute of Vaccines and...

Completed

Trial of Tolerability, Safety and Immunogenicity of the Flu-M Vaccine in Children Between 6 Months and 9 Years Old

Influenza, Human | Vaccination; Infection | Vaccines

Russian Federation
POLYSAN Scientific & Technological Pharmaceutical...

Recruiting

Cycloferon for Post-exposure Prophylaxis of Acute Respiratory Viral Infections and Influenza

Influenza | Acute Respiratory Infection

Russian Federation
Valenta Pharm JSC

Completed

Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections

Influenza, Human | Common Cold | Acute Respiratory Infection | Flu | Viral Infection

Russian Federation
Nearmedic Plus LLC

Completed

Kagocel® for the Prevention of ARVI and Influenza in Adults Health Care Workers

Influenza | Respiratory Viral Infection | Acute Upper Respiratory Tract Infection

Russian Federation
St. Petersburg Research Institute of Vaccines and...

Completed

Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vaccine

Vaccine Reaction | Influenza | Influenza, Human | Vaccination; Infection | Influenza Viral Infections

Russian Federation
St. Petersburg Research Institute of Vaccines and...

Completed

Trial of Tolerability, Reactogenicity, Safety and Immunogenicity of Flu-M [Inactivated Split Influenza Vaccine] in Pregnant Women

Influenza, Human | Vaccination; Infection | Vaccines

Russian Federation
Valenta Pharm JSC

Completed

A Study to Evaluate the Safety and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections

Influenza | Respiratory Viral Infection

Russian Federation
Valenta Pharm JSC

Recruiting

Efficacy and Safety of Ingavirin®, Capsules, 60 mg, in Children With Influenza and Other Acute Respiratory Viral Infections

Influenza, Human | Common Cold | Acute Respiratory Infection

Russian Federation
Valenta Pharm JSC

Completed

A Study to Evaluate the Safety, Tolerability and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections

Influenza | Viral Respiratory Infection | Acute Viral Upper Respiratory Infections

Russian Federation
Valenta Pharm JSC

Completed

Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Patients 13-17 y.o.

Influenza, Human | Common Cold | Acute Respiratory Infection | Viral Infection

Russian Federation
Viriom

Completed

Dose Range Study to Evaluate the Efficacy and Safety of AV5080 in Patients With Influenza

Influenza

Russian Federation
Nearmedic Plus LLC

Completed

Treatment of Influenza in Routine Clinical Practice (FLU-EE)

Influenza | Acute Upper Respiratory Infection

Armenia, Georgia, Moldova, Republic of, Russian Federation
Materia Medica Holding

Suspended

Clinical Trial of Efficacy and Safety of ММН-407 in the Treatment of Influenza in Outpatient Adults

Influenza

Russian Federation
PHARMENTERPRISES LLC
RSV Therapeutics LLC

Completed

Study to Assess Efficacy and Safety of XC221 200 mg in the Treatment of Influenza or Other ARVI

Influenza | Acute Respiratory Viral Infections

Russian Federation
Federal Research Institute of Pediatric Hematology...

Recruiting

Modification of the Human Colon and Oral Microbiome by Allogenic HSCT

Human Microbiome | HSCT

Russian Federation
Valenta Pharm JSC

Completed

Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections

Influenza, Human | Common Cold | Acute Respiratory Infection

Russian Federation
Valenta Pharm JSC
Atlant Clinical Ltd.

Completed

Efficacy and Safety Study of Ingavirin® to Treat Influenza and Other Acute Respiratory Viral Infections in Patients 3-6 y.o. (ACCORD)

Influenza | Common Cold

Russian Federation
PHARMENTERPRISES LLC

Completed

Study to Assess Efficacy and Safety of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections

Influenza | Acute Respiratory Viral Infections

Russian Federation
Valenta Pharm JSC

Completed

Efficacy and Safety Study of Ingavirin® 90 mg Once Daily to Treat Influenza and Other Acute Viral Infections in Adults

Influenza, Human | Common Cold | Acute Respiratory Infection

Russian Federation
GlaxoSmithKline

Terminated

Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza

Virus Diseases

United States, Sweden, Russian Federation, Romania
Valenta Pharm JSC

Completed

Pharmacokinetics and Bioequivalence of XC8 10 mg and 40 mg Tablets in Fasted Volunteers

Influenza | Respiratory Viral Infection

Russian Federation
Valenta Pharm JSC
Atlant Clinical Ltd.

Completed

Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Children 7-12 y.o.

Influenza, Human | Common Cold | Acute Respiratory Infection | Viral Infection

Russian Federation
PHARMENTERPRISES LLC

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers

Influenza | Acute Respiratory Infection

Russian Federation

Clinical Trials on Influenza, Human in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations